Evidence map›Paper›PMID 35786209›Full record

ArticleParasites & vectors2022

Regional seropositivity for Borrelia burgdorferi and associated risk factors: findings from the Rhineland Study, Germany.

Annabell Coors, Max J Hassenstein, Gérard Krause, Tobias Kerrinnes, Manuela Harries, Monique M B Breteler, Stefanie Castell

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Lyme borreliosis.Nature reviews. Disease primers · 2026
    Review
  3. Prevalence and Risk Factors ofPathogens (Basel, Switzerland) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Seroepidemiology ofMicroorganisms · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Annabell Coors *German Center for Neurodegenerative Diseases (DZNE), Population Health Sciences, Venusberg-Campus 1/99, 53127, Bonn, Germany.
Max J Hassenstein *Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.
Gérard KrauseDepartment of Epidemiology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.
Tobias KerrinnesDepartment of RNA-Biology of Bacterial Infections, Helmholtz Institute for RNA-Based Infection Research, Würzburg, Germany.
Manuela HarriesDepartment of Epidemiology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.
Monique M B Breteler *German Center for Neurodegenerative Diseases (DZNE), Population Health Sciences, Venusberg-Campus 1/99, 53127, Bonn, Germany. monique.breteler@dzne.de.
Stefanie Castell *Department of Epidemiology, Helmholtz Centre for Infection Research (HZI), Braunschweig, Germany.
Helmholtz Centre for Infection Research · DEGerman Center for Neurodegenerative Diseases · DEGerman Center for Infection Research · DEHelmholtz Institute for RNA-based Infection Research · DE

Funding

Initiative and Networking Fund of the Helmholtz Association RA-285/19
6 · The paper itself

Abstract

backgroundLyme borreliosis is the most prevalent vector-borne disease in Europe, and numbers might increase due to climate change. However, borreliosis is not notifiable in North Rhine-Westphalia (NRW), Germany. Hence, little is known about the current human seroprevalence in NRW. However, the proportion of Borrelia burgdorferi sensu lato-infected ticks has increased in a NRW nature reserve. The literature suggests increasing age and male sex as risk factors for seropositivity, whereas the influence of socioeconomic status is controversial. Thus, we aimed to determine regional seropositivity for Borrelia burgdorferi sensu lato (B. burgdorferi s.l.) and its risk factors in the Rhineland Study population in Bonn, NRW, and to compare it with previous surveys to evaluate potential effects of climate change.

methodsWe assessed seropositivity in 2865 Rhineland Study participants by determining immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies for B. burgdorferi s.l. using a two-step algorithm combining enzyme-linked immunosorbent assay tests and line immunoblots. We calculated the odds of being classified as IgG or IgM positive as a function of age, sex, and educational level using binomial logistic regression models. We applied varying seropositivity classifications and weights considering age, sex and education to compensate for differences between the sample and regional population characteristics.

resultsIgG antibodies for B. burgdorferi s.l. were present in 2.4% and IgM antibodies in 0.6% of the participants (weighted: 2.2% [IgG], 0.6% [IgM]). The likelihood of IgG seropositivity increased by 3.0% (95% confidence interval [CI] 1.5-5.2%) per 1 year increase in age. Men had 1.65 times the odds for IgG seropositivity as women (95% CI 1.01-2.73), and highly educated participants had 1.83 times the odds (95% CI 1.10-3.14) as participants with an intermediate level of education. We found no statistically significant link between age, sex, or education and IgM seropositivity. Our weighted and age-standardized IgG seroprevalence was comparable to the preceding serosurvey German Health Interview and Examination Survey for Adults (DEGS) for NRW.

conclusionsWe confirmed that increasing age and male sex are associated with increased odds for IgG seropositivity and provide evidence for increased seropositivity in the highly educated group. B. burgdorferi s.l. seropositivity remained constant over the past decade in this regional German population.

Indexed as

Borrelia burgdorferiAdultFemaleGermanyHumansImmunoglobulin GImmunoglobulin MMaleSeroepidemiologic StudiesImmunoglobulin GImmunoglobulin MAntibodiesEnzyme-linked immunosorbent assayGermanyImmunoblottingImmunoglobulin GImmunoglobulin MLyme diseaseSeroepidemiological studiesTick-borne diseasesTicks

Identifiers

PMID35786209
PMCPMC9252056
OpenAlexW4283800976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.